EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Relationship between sodium-glucose cotransporter 2 inhibitors and kidney neoplasm: systematic review and meta-analysis

Mohammadreza Nowroozi, Ali Khalilzadeh, Seyed Amir Banikarim, Houshang Sanadgol, Rasoul Jafari Arismani, Ahmadreza Maghsoudi, Peyman Khajehnabi, Zahed Karimi, Naeem Nikpour

Journal of Nephropathology · 19.04.2026 · 15 · e27706

DOI: 10.34172/jnp.2026.27706 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Nephropathology, online erschienen am 19.04.2026. Verfasst von Mohammadreza Nowroozi und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Kidney cancer is a common tumor of the urinary system, and existing data on the relationship between sodium–glucose cotransporter 2 (SGLT2) inhibitors use and kidney cancer are inconsistent. Therefore, this study aimed to investigate the association between SGLT2 inhibitor use and the risk of developing kidney cancer. Materials and Methods: This study was designed as a systematic review and meta-analysis following the PRISMA guidelines. Accordingly, a comprehensive search was conducted in the Cochrane, Scopus, Web of Science, Embase, and PubMed databases, as well as the Google Scholar search engine, up to January 5, 2026. Data analysis was performed using STATA version 14.

Results

The results showed that the association between the use of SGLT2 inhibitors (OR: 1.14, 95% CI: 0.86–1.52), dapagliflozin (OR: 1.67, 95% CI: 0.47–5.93), canagliflozin (OR: 1.59, 95% CI: 0.61–4.15), and empagliflozin (OR: 1.31, 95% CI: 0.52–3.27) with the risk of kidney cancer was not statistically significant. However, SGLT2 inhibitor use was associated with a reduced risk of renal cell carcinoma (RCC) (OR: 0.69, 95% CI: 0.63–0.76). In contrast, compared with dipeptidyl peptidase‑4 (DPP‑4) inhibitors, SGLT2 inhibitor use was linked to an increased risk of kidney cancer (OR: 1.64, 95% CI: 1.11–2.43).

Conclusion

In conclusion, the use of SGLT2 inhibitors did not affect the incidence of kidney cancer, but it was associated with a 31% reduction in the risk of RCC. In contrast, compared with DPP‑4 inhibitors, SGLT2 inhibitor use increased the risk of kidney cancer by 64%. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420261293668) and Research Registry (UIN; reviewregistry2078) websites.

Zitieren

APA

Nowroozi, M., Khalilzadeh, A., Banikarim, S. A., Sanadgol, H., Arismani, R. J., Maghsoudi, A., Khajehnabi, P., Karimi, Z., & Nikpour, N. (2026). Relationship between sodium-glucose cotransporter 2 inhibitors and kidney neoplasm: systematic review and meta-analysis. Journal of Nephropathology, 15, e27706. https://doi.org/10.34172/jnp.2026.27706

Vancouver

Nowroozi M, Khalilzadeh A, Banikarim SA, Sanadgol H, Arismani RJ, Maghsoudi A, et al. Relationship between sodium-glucose cotransporter 2 inhibitors and kidney neoplasm: systematic review and meta-analysis. Journal of Nephropathology. 2026;15:e27706. doi:10.34172/jnp.2026.27706

BibTeX
@article{Nowroozi2026,
  author = {Nowroozi, Mohammadreza and Khalilzadeh, Ali and Banikarim, Seyed Amir and Sanadgol, Houshang and Arismani, Rasoul Jafari and Maghsoudi, Ahmadreza and Khajehnabi, Peyman and Karimi, Zahed and Nikpour, Naeem},
  title = {Relationship between sodium-glucose cotransporter 2 inhibitors and kidney neoplasm: systematic review and meta-analysis},
  journal = {Journal of Nephropathology},
  year = {2026},
  volume = {15},
  pages = {e27706},
  doi = {10.34172/jnp.2026.27706}
}
Kostenlos starten →